AstraZeneca to acquire Icosavax

eAwazMedicine

London – AstraZeneca has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. The proposed acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus (RSV), strengthening AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with Icosavax’s lead investigational vaccine …

MODERNA ASKS HEALTH CANADA TO REVIEW ITS RSV VACCINE, mRNA-1345

eAwazMedicine

mRNA-1345 is an investigational vaccine for the prevention of RSV in adults aged 60 years or older TORONTO – Moderna Biopharma Canada Corp. has announced the filing of a New Drug Submission (NDS) to Health Canada for mRNA-1345, its investigational vaccine candidate for the prevention of RSV in adults aged 60 years or older. This is the first mRNA vaccine …